A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.
Source: Pixabay

A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.

The US Food and Drug Administration (FDA) has just awarded Breakthrough Therapy Designation to a drug (OMS721) being developed to treat thrombotic microangiopathy that has developed as a result of haematopoietic stem…

Continue Reading A Treatment for Thrombotic Microangiopathy Has Been Awarded Breakthrough Status by the F.D.A.